Multimodal imaging for identification and classification of circulating tumor cells

Author(s):  
Maria Mangini ◽  
Maria Antonietta Ferrara ◽  
Gianluigi Zito ◽  
Stefano Managò ◽  
Giuseppe Coppola ◽  
...  
Oncotarget ◽  
2016 ◽  
Vol 7 (11) ◽  
pp. 12748-12760 ◽  
Author(s):  
James Che ◽  
Victor Yu ◽  
Manjima Dhar ◽  
Corinne Renier ◽  
Melissa Matsumoto ◽  
...  

2019 ◽  
Vol 9 (1) ◽  
Author(s):  
Carlos Aguilar-Avelar ◽  
Brenda Soto-García ◽  
Diana Aráiz-Hernández ◽  
Juan F. Yee-de León ◽  
Miguel Esparza ◽  
...  

Abstract Circulating tumor cells (CTCs) have the potential of becoming the gold standard marker for cancer diagnosis, prognosis and monitoring. However, current methods for its isolation and characterization suffer from equipment variability and human operator error that hinder its widespread use. Here we report the design and construction of a fully automated high-throughput fluorescence microscope that enables the imaging and classification of cancer cells that were labeled by immunostaining procedures. An excellent agreement between our machine vision-based approach and a state-of-the-art microscopy equipment was achieved. Our integral approach provides a path for operator-free and robust analysis of cancer cells as a standard clinical practice.


2012 ◽  
Vol 85 (1) ◽  
pp. 398-403 ◽  
Author(s):  
Ivaylo Ivanov ◽  
Jessica Stojcic ◽  
Aleksandra Stanimirovic ◽  
Edward Sargent ◽  
Robert K. Nam ◽  
...  

2021 ◽  
Vol 22 (23) ◽  
pp. 13073
Author(s):  
María Lola Espejo-Cruz ◽  
Sandra González-Rubio ◽  
Javier Zamora-Olaya ◽  
Víctor Amado-Torres ◽  
Rafael Alejandre ◽  
...  

Hepatocellular carcinoma (HCC) is the fifth most common neoplasm and a major cause of cancer-related death worldwide. There is no ideal biomarker allowing early diagnosis of HCC and tumor surveillance in patients receiving therapy. Liquid biopsy, and particularly circulating tumor cells (CTCs), have emerged as a useful tool for diagnosis and monitoring therapeutic responses in different tumors. In the present manuscript, we evaluate the current evidence supporting the quantitative and qualitative assessment of CTCs as potential biomarkers of HCC, as well as technical aspects related to isolation, identification, and classification of CTCs. Although the dynamic assessment of CTCs in patients with HCC may aid the decision-making process, there are still many uncertainties and technical caveats to be solved before this methodology has a true impact on clinical practice guidelines. More studies are needed to identify the optimal combination of surface markers, to increase the efficiency of ex-vivo expansion of CTCs, or even to target CTCs as a potential therapeutic strategy to prevent HCC recurrence after surgery or to hamper tumor progression and extrahepatic spreading.


2020 ◽  
Vol 18 (1) ◽  
Author(s):  
Jing Chen ◽  
Changsheng Ye ◽  
Jianyu Dong ◽  
Shunwang Cao ◽  
Yanwei Hu ◽  
...  

Sign in / Sign up

Export Citation Format

Share Document